IMHOTEP phase II trial of neoadjuvant pembrolizumab in dMMR/MSI localized cancers: Results of the digestive non-colorectal cancer cohorts

被引：0
|
作者：
de la Fouchardiere, C. [1 ]
Zaanan, A. [2 ]
Cohen, R. [3 ]
Le Sourd, S. M. [4 ]
Tougeron, D. [5 ]
Soularue, E. [6 ]
Dubreuil, O. [7 ]
Williet, N. [8 ]
Samalin-Scalzi, E. [9 ]
Piessen, G. [10 ]
Hautefeuille, V. [11 ]
Jary, M. [12 ]
Ben Abdelghani, M. [13 ]
Evesque, L. [14 ]
Rochigneux, P. [15 ]
Blanc, E. [16 ]
Bibeau, F. [17 ]
DeMontfort, A. [18 ]
Coutzac, C. [19 ]
机构：
[1] Ctr Leon Berard, Med Oncol, Lyon, France
[2] Hop Europeen Georges Pompidou, AP HP, Digest Oncol, Paris, France
[3] Hop St Antoine, Med Oncol, Paris, France
[4] Ctr Eugene Marquis, Digest Oncol, Rennes, France
[5] CHU Poitiers, Jean Bernard Hop, Gastroenterol & Digest Oncol, Poitiers, France
[6] Inst Mutualiste Montsouris, Med Oncol, Paris, France
[7] Gh Diaconesses Croix St Simon, Med Oncol, Paris, France
[8] Hop Nord St Priest Jarez, Gastroenterol & Digest Oncol, St Priest En Jarez, France
[9] ICM Inst Canc Montpellier, Med Oncol, Montpellier, France
[10] CHU Claude Huriez, Digest Surg, Lille, France
[11] CHU Amiens Picardie, Gastroenterol & Digest Oncol, Amiens, France
[12] CHU Clermont Ferrand Site Estaing, Med Oncol, Clermont Ferrand, France
[13] ICANS Inst Cancerol Strasbourg Europe, Med Oncol, Strasbourg, France
[14] Ctr Anticancer Antoine Lacassagne, GI Oncol, Nice, France
[15] IPC Inst Paoli Calmettes, Med Oncol, Marseille, France
[16] Ctr Leon Berard, Clin Res, Lyon, France
[17] CHU Besancon, Pathol, Besancon, France
[18] Ctr Leon Berard, Biostat, Lyon, France
[19] Ctr Leon Berard, Digest Oncol, Lyon, France
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1514
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1448P
引用
收藏
页码：S899 / S900
页数：2
相关论文
共 50 条
  • [1] IMHOTEP Phase II trial of neoadjuvant pembrolizumab in dMMR/MSI tumors: Results of the colorectal cancer cohort
    de la Fouchardiere, C.
    Zaanan, A.
    Cohen, R.
    Le Sourd, S. M.
    Tougeron, D.
    Soularue, E.
    Dubreuil, O.
    Williet, N.
    Samalin-Scalzi, E.
    Piessen, G.
    Hautefeuille, V.
    Jary, M.
    Ben Abdelghani, M.
    Evesque, L.
    Rochigneux, P.
    Blanc, E.
    Bibeau, F.
    DeMontfort, A.
    Coutzac, C.
    ANNALS OF ONCOLOGY, 2024, 35 : S429 - S429
  • [2] Assessment of pathologic response in the colorectal cancer cohort of the IMHOTEP phase II trial of neoadjuvant pembrolizumab in dMMR/MSI tumors.
    Bibeau, Frederic
    Mansar, Racha
    Monnien, Franck
    De Montfort, Aymeric
    Blanc, Ellen
    Coutzac, Clelia
    de la Fouchardiere, Christelle
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 241 - 241
  • [3] KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer
    Andre, Thierry
    Pietrantonio, Filippo
    Avallone, Antonio
    Gumus, Mahmut
    Wyrwicz, Lucjan
    Kim, Jong Gwang
    Yalcin, Suayib
    Kwiatkowski, Mariusz
    Lonardi, Sara
    Zolnierek, Jakub
    Odeleye-Ajakaye, Amos
    Leconte, Pierre
    Fogelman, David
    Kim, Tae Won
    FUTURE ONCOLOGY, 2023, 19 (37) : 2445 - 2452
  • [4] Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results
    O'Malley, David M.
    Bariani, Giovani M.
    Cassier, Philippe A.
    Marabelle, Aurelien
    Hansen, Aaron R.
    Acosta, Ana De Jesus
    Miller Jr, Wilson H.
    Safra, Tamar
    Italiano, Antoine
    Mileshkin, Linda
    Yao, Lili
    Gozma, Alexander
    Jin, Fan
    Maio, Michele
    GYNECOLOGIC ONCOLOGY, 2025, 193 : 130 - 135
  • [5] Pembrolizumab vs chemotherapy for MSI-high/dMMR metastatic colorectal cancer: Asia subgroup of phase 3 KEYNOTE-177
    Yoshino, Takayuki
    Kim, Tae Won
    Yong, Wei Peng
    Shiu, Kai-Keen
    Jensen, Benny Vittrup
    Jensen, Lars Henrik
    Smith, Denis
    Garcia-Carbonero, Rocio
    Alcaide-Garcia, Julia
    Gibbs, Peter
    De la Fouchardiere, Christelle
    Rivera, Fernando
    Elez, Elena
    Bendell, Johanna
    Le, Dung T.
    Yang, Ping
    Farooqui, Mohammed
    Marinello, Patricia
    Diaz, Luis A.
    Andre, Thierry
    ANNALS OF ONCOLOGY, 2021, 32 : S284 - S284
  • [6] Results of phase I-II bridging study for Nous-209, a neoantigen cancer immunotherapy, in combination with pembrolizumab as first line treatment in patients with advanced dMMR/MSI-h colorectal cancer
    Overman, Michael J.
    Maurel, Joan
    Oberstein, Paul Eliezer
    Rosello-Keranen, Susana
    Le, Dung T.
    Pedersen, Katrina Sophia
    Mukherjee, Sarbajit
    D'Alise, Anna Morena
    Leoni, Guido
    Siani, Loredana
    Scarselli, Elisa
    Faivre, Thea
    Delaite, Patricia
    Gogov, Sven
    Fakih, Marwan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Neoadjuvant toripalimab plus CapeOX in patients with localized dMMR/MSI-H gastric or esophagogastric junction adenocarcinoma (GC/EGJC): Results from the cohort C of phase II NICE trial.
    Zhao, Liying
    Liu, Hao
    Hu, Yanfeng
    Yu, Jiang
    Yuan, Shu-Qiang
    Wang, Wei
    Jiang, Junliang
    Chen, Xinhua
    Liang, Li
    Yu, Lina
    Huang, Mengli
    Li, Fengping
    Lin, Tian
    Zhao, Mingli
    Chen, Yaoxu
    Chen, Tao
    Chen, Hao
    Li, Guoxin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 349 - 349
  • [8] Circulating tumor DNA as a predictive biomarker for pathologic response after treatment with neoadjuvant immunotherapy for localized dMMR/MSI-H colorectal cancer.
    LaPelusa, Michael Brian
    San Lucas, Francis A.
    Iorgulescu, Bryan
    Patel, Keyur P.
    You, Nancy
    Foo, Wai Chin
    Maru, Dipen M.
    Kopetz, Scott
    Ludford, Kaysia
    Morris, Van K., II
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Immune checkpoint inhibitors (ICIs) in deficient mismatch repair (dMMR)/microsatellite instability (MSI) non-colorectal cancers: Real world Indian data and the use of alternative dosing.
    Vaddoriya, Dishant
    Ramaswamy, Anant
    Agarwala, Vivek
    Tiwari, Priya
    Talreja, Vikas
    Baghmar, Saphalta
    Sardana, Shefali
    Gupta, Vineet Govinda
    Bajpai, Peyush
    Chandrakanth, M., V
    Ostwal, Vikas S.
    Raina, Shivani
    Shenoy, Vallish
    Bhargava, Prabhat Ghanshyam
    Lavingia, Viraj Kiran
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 347 - 347
  • [10] Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
    Okuma, Hitomi S.
    Watanabe, Keisuke
    Tsuchihashi, Kenji
    Machida, Ryunosuke
    Sadachi, Ryo
    Hirakawa, Akihiro
    Ariyama, Hiroshi
    Kanai, Masashi
    Kamikura, Masahisa
    Anjo, Kenta
    Hiramitsu, Akari
    Sekine, Shigeki
    Okita, Natsuko
    Mano, Hiroyuki
    Nishikawa, Hiroyoshi
    Nakamura, Kenichi
    Yonemori, Kan
    CLINICAL CANCER RESEARCH, 2023, 29 (24) : 5079 - 5086
12345